Should I buy or sell Eloxx Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eloxx Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ELOX shares. View ELOX analyst ratings or view top-rated stocks .

What is Eloxx Pharmaceuticals' stock price target for 2024?

1 Wall Street research analysts have issued 1 year price objectives for Eloxx Pharmaceuticals' stock. Their ELOX share price targets range from $55.00 to $55.00. On average, they expect the company's share price to reach $55.00 in the next year. This suggests a possible upside of 4,900.0% from the stock's current price. View analysts price targets for ELOX or view top-rated stocks among Wall Street analysts .

How have ELOX shares performed in 2023?

Eloxx Pharmaceuticals' stock was trading at $1.82 at the beginning of 2023. Since then, ELOX stock has decreased by 39.6% and is now trading at $1.10. View the best growth stocks for 2023 here .

How were Eloxx Pharmaceuticals' earnings last quarter?

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) posted its earnings results on Monday, November, 13th. The company reported ($1.31) earnings per share for the quarter, topping the consensus estimate of ($1.97) by $0.66.

What is Greg Williams' approval rating as Eloxx Pharmaceuticals' CEO?

1 employees have rated Eloxx Pharmaceuticals Chief Executive Officer Greg Williams on Glassdoor.com . Greg Williams has an approval rating of 49% among the company's employees. This puts Greg Williams in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Eloxx Pharmaceuticals to a friend.

Who are Eloxx Pharmaceuticals' major shareholders?

Eloxx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (10.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel E Geffken , Pontifax Management 4 GP (20 and Rajesh B Parekh . View institutional ownership trends .

How do I buy shares of Eloxx Pharmaceuticals?

Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Eloxx Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ELOX)

$1.10

-0.01 (-0.90%)

(As of 12/6/2023 ET)

Compare

Today's Range: $1.10
▼
$1.12
50-Day Range: $1.07
▼
$4.91
52-Week Range: $0.95
▼
$10.90

Volume: 2,584 shs
Average Volume: 436,871 shs
Market Capitalization: $3.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $55.00

Eloxx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 4,900.0% Upside
$55.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($7.91) to ($7.39) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.68 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Eloxx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $55.00, Eloxx Pharmaceuticals has a forecasted upside of 4,900.0% from its current price of $1.10.
Amount of Analyst Coverage
Eloxx Pharmaceuticals has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for ELOX.

0.0

Dividend Strength

Dividend Yield
Eloxx Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Eloxx Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ELOX.

0.0

News and Social Media Coverage

MarketBeat Follows
Only 1 people have added Eloxx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eloxx Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
20.20% of the stock of Eloxx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 8.64% of the stock of Eloxx Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Eloxx Pharmaceuticals are expected to grow in the coming year, from ($7.91) to ($7.39) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eloxx Pharmaceuticals is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eloxx Pharmaceuticals is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Eloxx Pharmaceuticals Stock (NASDAQ:ELOX)

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

ELOX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ELOX Stock News Headlines

November 22, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Biomea Fusion (BMEA) and Medtronic (MDT)

November 14, 2023 | msn.com

Hoth stock jumps on positive FDA feedback on drug HT-KIT

December 6, 2023 | Financial Alphas (Ad)

Lithium Discovery So BIG You Can't Miss it, Even From Space

With the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!

November 13, 2023 | finance.yahoo.com

Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update

November 8, 2023 | morningstar.com

Eloxx Pharmaceuticals Inc ELOX

October 9, 2023 | finance.yahoo.com

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria

September 21, 2023 | seekingalpha.com

Eloxx Pharmaceuticals prices $2M stock offering

September 19, 2023 | markets.businessinsider.com

Eloxx Pharmaceuticals Announces Registered Direct Offering - Quick Facts

December 6, 2023 | Financial Alphas (Ad)

Lithium Discovery So BIG You Can't Miss it, Even From Space

September 19, 2023 | finance.yahoo.com

Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

September 18, 2023 | finance.yahoo.com

Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

September 8, 2023 | msn.com

Eloxx moves ahead with plans with gene therapy for rare kidney disorder

September 7, 2023 | finance.yahoo.com

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

August 30, 2023 | fool.com

Eloxx Pharmaceuticals (NASDAQ: ELOX)

August 15, 2023 | msn.com

Eloxx reports all patients in Phase II Alport syndrome trial have improved

August 14, 2023 | markets.businessinsider.com

Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update

August 14, 2023 | msn.com

Eloxx Pharma (NASDAQ:ELOX) Rises On Promising Phase 2 Data In Alport Syndrome

August 14, 2023 | finance.yahoo.com

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

August 14, 2023 | finance.yahoo.com

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

July 11, 2023 | msn.com

Eloxx, Airbnb, Tesla, PainReform, Roku: Why These 5 Stocks Are Drawing Investor Attention Today

July 11, 2023 | benzinga.com

Eloxx Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Up 111.3%

July 11, 2023 | msn.com

Oppenheimer Maintains Eloxx Pharmaceuticals (ELOX) Outperform Recommendation

July 11, 2023 | benzinga.com

Why Eloxx Pharmaceuticals (ELOX) Stock Is Soaring Tuesday

July 11, 2023 | benzinga.com

Oppenheimer Maintains Outperform on Eloxx Pharmaceuticals, Raises Price Target to $55

July 10, 2023 | finance.yahoo.com

Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit

June 28, 2023 | finance.yahoo.com

Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02

June 21, 2023 | finance.yahoo.com

Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome

See More Headlines

Receive ELOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ELOX
CUSIP: N/A
CIK: 1035354
Web: www.eloxxpharma.com
Phone: (781) 577-5300
Fax: 908-864-4440
Employees: 18
Year Founded: 2013

Price Target and Rating

Average Stock Price Target: $55.00
High Stock Price Target: $55.00
Low Stock Price Target: $55.00
Potential Upside/Downside: +4,810.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($9.07)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,060,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -203.00%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.24
Quick Ratio: 0.24

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($4.92) per share
Price / Book: -0.23

Miscellaneous

Outstanding Shares: 3,143,000
Free Float: 2,508,000
Market Cap: $3.52 million
Optionable: Not Optionable
Beta: 2.65

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Sumit Aggarwal M.B.A. (Age 50)
President, CEO & Director
Comp: $839.67k
Mr. Daniel E. Geffken M.B.A. (Age 66)
Interim CFO, Principal Financial Officer & Principal Accounting Officer
Comp: $63.96k
Ms. Barbara Ryan
Investor Relations Officer
Dr. Ali Hariri M.D.
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

Armistice Capital LLC
Bought 275,000 shares on 11/15/2023
Ownership: 10.000%

View All Institutional Transactions

ELOX Stock Analysis - Frequently Asked Questions

Should I buy or sell Eloxx Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eloxx Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ELOX shares.
View ELOX analyst ratings or view top-rated stocks.
What is Eloxx Pharmaceuticals' stock price target for 2024?: 1 Wall Street research analysts have issued 1 year price objectives for Eloxx Pharmaceuticals' stock. Their ELOX share price targets range from $55.00 to $55.00. On average, they expect the company's share price to reach $55.00 in the next year. This suggests a possible upside of 4,900.0% from the stock's current price.
View analysts price targets for ELOX or view top-rated stocks among Wall Street analysts.
How have ELOX shares performed in 2023?: Eloxx Pharmaceuticals' stock was trading at $1.82 at the beginning of 2023. Since then, ELOX stock has decreased by 39.6% and is now trading at $1.10.
View the best growth stocks for 2023 here.
How were Eloxx Pharmaceuticals' earnings last quarter?: Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) posted its earnings results on Monday, November, 13th. The company reported ($1.31) earnings per share for the quarter, topping the consensus estimate of ($1.97) by $0.66.

What is Greg Williams' approval rating as Eloxx Pharmaceuticals' CEO?: 1 employees have rated Eloxx Pharmaceuticals Chief Executive Officer Greg Williams on Glassdoor.com. Greg Williams has an approval rating of 49% among the company's employees. This puts Greg Williams in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Eloxx Pharmaceuticals to a friend.
Who are Eloxx Pharmaceuticals' major shareholders?: Eloxx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (10.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel E Geffken, Pontifax Management 4 GP (20 and Rajesh B Parekh.
View institutional ownership trends.
How do I buy shares of Eloxx Pharmaceuticals?: Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ELOX) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Eloxx Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ELOX)

Eloxx Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Eloxx Pharmaceuticals Stock (NASDAQ:ELOX)

ELOX Stock Price History

ELOX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ELOX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™